Introduction
============

HIV-infected individuals are at higher risk for acquiring HDV. We sought to study the prevalence, genotypes, and associated risk factors causing HDV infection in HIV-infected individuals from an area with high prevalence of hepatitis B virus infection.

Materials and methods
=====================

A multicenter study of 341 (22.1%) HBsAg+ from 1543 HIV-infected patients was conducted from 2005 through 2011. Blood samples were collected and analyzed for the presence of antibody to HDV and to determine the genotype of HDV.

Results
=======

The overall prevalence of HDV infection among HBsAg+ carriers was 54.8% (187/341). However, the prevalence among different risk group was distinct. The prevalence of HDV was 73.6%, 13.5%, and 9.2% among HIV-infected IDUs, heterosexual, and MSM, respectively. The main circulating HDV subtypes in our study were genotype IV (60.5%), genotype II (27.6%), and genotype I (11.8%). Multivariate logistic regression analysis revealed that the major risk factor associated with HDV infection was injection drug use, following by HCV infection, HBsAg titer \>=250 IU/mL, and duration of injection drug use. A significant increase of cumulative seroprevalence of HDV with duration of IDU from 1 to 15 years was observed (OR: 1.20, 95% CI: 1.09-1.32, P\<0.01).

Conclusions
===========

Our study demonstrated high prevalence of HDV infection among HIV-infected IDUs. Effective strategies are needed to prevent injection drug use and to educate ongoing IDUs about the avoidance of practices that lead to infection with HIV, HCV, and HDV.
